Supriya Lifescience Ltd - 543434 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Satish Wagh Supriya Lifescience Ltd - 543434 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Satish Wagh
Buy Supriya Lifescience; target of Rs 278: KR Choksey
KR Choksey is bullish on Supriya Lifescience has recommended buy rating on the stock with a target price of Rs 278 in its research report dated February 17, 2023. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby enclose the transcript of the Earnings call held on Wednesday, February 15, 2023, at 11.00 A.M. IST to discuss operational and financial performance of the Company for the quarter and nine month ended December 31, 2022. Supriya Lifescience Ltd - 543434 - Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 30(5) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find below details of Key Managerial Personnel (KMP) of our company, for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s). Supriya Lifescience Ltd - 543434 - Audio Recording Of Earnings Call
In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the audio recording of the Company''s Earnings Call held today (i.e., February 15, 2023) regarding discussion on operational and financial performance for the third Quarter and nine months ended of FY 2022-2023 (Q3 & 9M FY23) is available on the Company''s website. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Newspaper Publication
With reference to the above captioned subject, please find enclosed newspaper advertisement published in Financial Express and Loksatta on Wednesday, February 15, 2023, containing extract of Unaudited Financial Results for the quarter and nine months ended December 31, 2022. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation. Supriya Lifescience Ltd - 543434 - Statement Of Deviation Or Variation In The Use Of Proceeds Of The Fresh Issue Of The Initial Public Offer Of The Company
Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended December 31, 2022 in the prescribed format. Further, we hereby confirm that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21, 2021. Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by ICICI Bank Limited for the quarter ended December 31, 2022 in respect of utilization of proceeds of the of the fresh issue of the IPO of the Company.